Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$4.6 million.

  • Northwest Biotherapeutics' Enterprise Value fell 5515.48% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.6 million, marking a year-over-year decrease of 5515.48%. This contributed to the annual value of -$2.2 million for FY2024, which is 230.48% down from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Enterprise Value stood at -$4.6 million, which was down 5515.48% from -$4.3 million recorded in Q2 2025.
  • Northwest Biotherapeutics' 5-year Enterprise Value high stood at -$1.4 million for Q2 2023, and its period low was -$15.2 million during Q4 2021.
  • For the 5-year period, Northwest Biotherapeutics' Enterprise Value averaged around -$5.1 million, with its median value being -$4.3 million (2025).
  • In the last 5 years, Northwest Biotherapeutics' Enterprise Value crashed by 87748.69% in 2021 and then soared by 7052.37% in 2023.
  • Quarter analysis of 5 years shows Northwest Biotherapeutics' Enterprise Value stood at -$15.2 million in 2021, then soared by 54.08% to -$7.0 million in 2022, then skyrocketed by 69.48% to -$2.1 million in 2023, then fell by 2.3% to -$2.2 million in 2024, then crashed by 109.66% to -$4.6 million in 2025.
  • Its Enterprise Value stands at -$4.6 million for Q3 2025, versus -$4.3 million for Q2 2025 and -$2.8 million for Q1 2025.